Another study in HER2(+) breast cancer showed that CD45 can be used as a biomarker to guide the stratification of tumors sensitive to neoadjuvant-targeting HER2(+) therapy and guide subsequent therapy [43]. The gene discussed is ERBB2; the disease is breast carcinoma.